Controlled release of enhanced cross-hybrid IgGA Fc PD-L1 inhibitors using oncolytic adenoviruses-Reference-Cited by-同舟云学术

Controlled release of enhanced cross-hybrid IgGA Fc PD-L1 inhibitors using oncolytic adenoviruses

Published:2023-03 Issue: Volume:28 Page:264-276
ISSN:2372-7705
Container-title:Molecular Therapy - Oncolytics
language:en
Short-container-title:Molecular Therapy - Oncolytics

Author:

Hamdan Firas,Feodoroff Michaela^ORCID,Russo Salvatore,Fusciello Manlio,Feola Sara,Chiaro Jacopo,Antignani Gabriella,Greco Francesca,Leusen Jeanette,Ylösmäki Erkko,Grönholm Mikaela,Cerullo Vincenzo^ORCID

Publisher

Elsevier BV

Subject

Pharmacology (medical),Cancer Research,Oncology,Molecular Medicine

Reference28 articles.

1. Cancer incidence and risk factors after solid organ transplantation;Vajdic;Int. J. Cancer,2009

2. Perforin-mediated cytotoxicity is critical for surveillance of spontaneous lymphoma;Smyth;J. Exp. Med.,2000

3. Immune evasion in cancer: mechanistic basis and therapeutic strategies;Vinay;Semin. Cancer Biol.,2015

4. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death;Ishida;EMBO J.,1992

5. Anti–PD-1/PD-L1 therapy of human cancer: past, present, and future;Chen;J. Clin. Invest.,2015

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Novel peptide-based oncolytic vaccine for enhancement of adaptive antitumor immune response via co-engagement of innate Fcγ and Fcα receptors;Journal for ImmunoTherapy of Cancer;2024-03

2. Adenovirotherapy delivering cross-hybrid IgGA Fc engineering PD-L1 inhibitors for enhanced cancer immunotherapy;Molecular Therapy - Oncolytics;2023-06